---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-239422"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:17:55.939721+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Imara sells PDE9 program (tovinontrine) to Cardurion for $34.75M upfront plus milestones

## Summary
- Imara to receive $34.75M upfront at closing for tovinontrine and all PDE9 assets; plus $250k previously paid.
- Potential milestone payments: $10M for proof-of-concept/clinical milestones, $50M for regulatory/commercial milestones.
- Transaction requires stockholder approval; Board unanimously approved; termination fee of $1.5M.
- Retention agreements amended for CEO Rahul Ballal and CFO/COO Michael Gray, with 50% payable on definitive agreement and 50% on closing.
- Company will continue evaluating strategic alternatives post-sale, including possible liquidation.

## SEC filing metadata
- accession: 0001193125-22-239422
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312522239422/0001193125-22-239422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312522239422/d396958d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-239422
- JSON: https://secwatch.observer/filing/0001193125-22-239422.json
- Plain text: https://secwatch.observer/filing/0001193125-22-239422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.